The field of immunometabolism has attracted growing attention in recent years due to the high potential for the development of cancer immunotherapies. Upon activation, T lymphocytes (T cells) undergo significant metabolic changes that allow them to mediate immune responses. Stimulating these and other immune cells has important outcomes beyond energy production (Fig. 1). A key
Hydrogels are a 3-D network of highly absorbent polymers that have been investigated since the late 20th century for various biomedical applications, including drug delivery, wound healing, and tissue engineering. Their highly absorbent nature gives them a flexibility similar to natural tissues and allows oxygen, nutrients, proteins, and other biomolecules to readily enter and nourish
Dimethyl sulfoxide (DMSO) is an organic solvent that is widely used as cryoprotectant for freezing cells and tissues. Clinically, DMSO is considered a potent anti-inflammatory, nerve blocker (analgesic), diuretic, vasodilator and muscle relaxer. In cells, DMSO is used to induce differentiation, as a free radical scavenger, and most notably, to prevent ice formation during cryopreservation.
Akron Biotech recently participated in the ARMI | BioFabUSA Spring Summit in Manchester, NH, joining several leading research institutions and companies to continue charting a path forward for the tissue engineering industry. If we think about innovation as a process of bringing old ideas together to make new things, then ARMI is uniquely suited to
Many cancer therapies that have emerged in the past decade have been developed to increase anti-tumor immunity. Specifically, these therapies promote innate and adaptive immune responses and equip the body’s own immune system to work as a weapon against tumors. Currently, most approaches have focused on enhancing T cell responses. One such approach targets inhibitory
Scientists from Boston Children’s Hospital and Massachusetts Institute of Technology (MIT) have used alpaca-derived nanobodies to create a novel approach to CAR T cell therapy that addresses the challenge of treating patients with solid tumor cancers. Currently, CAR-T cell immunotherapy has been applied to the treatment of non-solid tumors such as acute lymphoblastic leukemia (ALL).
Following successful clinical studies, the FDA and regulatory authorities around the world have approved the use of axicabtagene ciloleucel (Yescarta™) for patients with large-B-cell lymphomas and tisagenlecleucel (Kymriah™) for adults with certain types of non-Hodgkin lymphoma. Despite its success as a novel way of treating cancer, physician scientists are realizing that 30%-50% of patients who
The Akron team recently attended the 4th Innate Killer Summit, held in in San Diego, California. The conference provided an excellent opportunity to participate in presentations and workshops covering cutting-edge research, recent clinical data, and commercial developments in the growing NK cell therapy market. More than 250 attendees collaborated and shared knowledge on ways we
The blood brain barrier (BBB) is an important physiological wall protecting the central nervous system (CNS) from potentially harmful materials in the blood. However, this protective mechanism also blocks the entry of many drugs. The brain is one of the most challenging organs to access, often requiring the use of fine-tuned and precise drug delivery
The preservation of biological samples is critical to the success of experimental studies and clinical treatments in the emergent field of immunotherapy. Cryopreservation – keeping cells at sub-zero temperatures – slows metabolic activity significantly, enabling storage and transportation, as well as a return to functionality upon thaw. Of course, it’s not as simple as placing